GlassScriptPhysician profile
Laura R Clark
NPI 1831484013
$4,460.34
in general payments reported to CMS, 2019-2025
23 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $22.06 · 2023: $839 · 2024: $1,335 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,619 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,619.14 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,033.39 | 2021-2025 | |
| Genzyme Corporation | $925.79 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $487.76 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $410.23 | 2021-2025 | Tremfya |
| Ucb, INC. | $296.33 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $218.63 | 2023-2025 | Ilumya |
| Leo Pharma INC. | $203.23 | 2021-2025 | Adbry |
| Lilly USA, LLC | $122.32 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $95.68 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $88.65 | 2023-2025 | Sotyktu |
| Incyte Corporation | $72.86 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $68.90 | 2024-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $68.75 | 2021-2025 | |
| Amgen INC. | $67.83 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $56.88 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $48.54 | 2025 | Sofdra |
| Allergan, INC. | $43.29 | 2021 | |
| Organogenesis INC. | $43.11 | 2025 | Affinity, Puraply Wound Matrix |
| Mayne Pharma Commercial LLC | $30.38 | 2024 | |
| Journey Medical Corporation | $23.36 | 2023 | |
| Almirall LLC | $21.55 | 2025 | Klisyri |
| Verrica Pharmaceuticals INC. | $20.78 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.